Incyte (INCY) Income from Continuing Operations (2010 - 2026)
Incyte posted quarterly Income from Continuing Operations of 303330000.0 for Q1 2026, up 91.73% year-on-year from 158203000.0 in Q1 2025, and up 1.35% on a QoQ basis from 299279000.0 in Q4 2025.
Incyte (INCY) has 17 years of Income from Continuing Operations data on file, last reported at 303330000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 91.73% year-over-year to 303330000.0; the trailing twelve-month figure through Mar 2026 stood at 1431777000.0 (up 6631.44% YoY), and the FY2025 full-year result was 1286650000.0, up 3844.96% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 303330000.0, up from 299279000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 424169000.0 in Q3 2025 and bottomed at 444601000.0 in Q2 2024.
- The 5-year median for Income from Continuing Operations is 169548000.0 (2024), against an average of 150638470.59.
- Peak annual rise in Income from Continuing Operations reached 681.22% in 2024, while the deepest fall reached 318.43% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 28461000.0 in 2022, then surged by 606.51% to 201079000.0 in 2023, then grew by 0.07% to 201212000.0 in 2024, then soared by 48.74% to 299279000.0 in 2025, then increased by 1.35% to 303330000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 303330000.0 (Q1 2026), 299279000.0 (Q4 2025), and 424169000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn | 303.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 303.33 Mn |
| Dec 31, 2025 | 299.28 Mn |
| Sep 30, 2025 | 424.17 Mn |
| Jun 30, 2025 | 405.00 Mn |
| Mar 31, 2025 | 158.20 Mn |
| Dec 31, 2024 | 201.21 Mn |
| Sep 30, 2024 | 106.46 Mn |
| Jun 30, 2024 | -444.60 Mn |
| Mar 31, 2024 | 169.55 Mn |
| Dec 31, 2023 | 201.08 Mn |
| Sep 30, 2023 | 171.27 Mn |
| Jun 30, 2023 | 203.55 Mn |
| Mar 31, 2023 | 21.70 Mn |
| Dec 31, 2022 | 28.46 Mn |
| Sep 30, 2022 | 112.78 Mn |
| Jun 30, 2022 | 161.43 Mn |
| Mar 31, 2022 | 37.99 Mn |
| Dec 31, 2021 | 563.85 Mn |
| Sep 30, 2021 | 181.77 Mn |
| Jun 30, 2021 | 149.46 Mn |
| Mar 31, 2021 | 53.52 Mn |
| Dec 31, 2020 | 149.85 Mn |
| Sep 30, 2020 | -15.21 Mn |
| Jun 30, 2020 | 290.30 Mn |
| Mar 31, 2020 | -720.64 Mn |
| Dec 31, 2019 | 110.63 Mn |
| Sep 30, 2019 | 128.27 Mn |
| Jun 30, 2019 | 105.32 Mn |
| Mar 31, 2019 | 102.31 Mn |
| Dec 31, 2018 | 68.60 Mn |
| Sep 30, 2018 | 29.18 Mn |
| Jun 30, 2018 | 52.41 Mn |
| Mar 31, 2018 | -41.14 Mn |
| Dec 31, 2017 | -149.63 Mn |
| Sep 30, 2017 | 36.05 Mn |
| Jun 30, 2017 | -12.48 Mn |
| Mar 31, 2017 | -187.08 Mn |
| Dec 31, 2016 | 8.87 Mn |
| Sep 30, 2016 | 36.88 Mn |
| Jun 30, 2016 | 34.43 Mn |
| Mar 31, 2016 | 24.05 Mn |
| Dec 31, 2015 | 55.18 Mn |
| Sep 30, 2015 | -39.58 Mn |
| Jun 30, 2015 | 9.29 Mn |
| Mar 31, 2015 | -18.36 Mn |
| Dec 31, 2014 | -36.94 Mn |
| Sep 30, 2014 | 59.29 Mn |
| Jun 30, 2014 | -36.87 Mn |
| Mar 31, 2014 | -33.96 Mn |
| Dec 31, 2013 | -42.87 Mn |
| Sep 30, 2013 | -22.04 Mn |
| Jun 30, 2013 | -2.57 Mn |
| Mar 31, 2013 | -15.67 Mn |
| Dec 31, 2012 | 18.78 Mn |
| Sep 30, 2012 | -21.71 Mn |
| Jun 30, 2012 | 4.04 Mn |
| Mar 31, 2012 | -45.43 Mn |
| Dec 31, 2011 | -55.08 Mn |
| Sep 30, 2011 | -53.08 Mn |
| Jun 30, 2011 | -51.87 Mn |
| Mar 31, 2011 | -26.51 Mn |
| Dec 31, 2010 | 32.54 Mn |
| Sep 30, 2010 | -31.70 Mn |
| Jun 30, 2010 | 3.04 Mn |
| Mar 31, 2010 | -35.73 Mn |